Xueying Zuo
Nanjing, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Impact of chronic obstructive pulmonary disease on the prognosis of patients with extensive-stage small-cell lung cancer treated with chemoimmunotherapy.
Journal: Translational lung cancer research
Published: April 24, 2026
CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancer.
Journal: Therapeutic advances in medical oncology
Published: December 04, 2025
Intrapleural dual blockade of IL-6 and PD-L1 reprograms CAF dynamics and the tumor microenvironment in lung cancer-associated malignant pleural effusion.
Journal: Respiratory research
Published: November 28, 2024
A random survival forest-based pathomics signature classifies immunotherapy prognosis and profiles TIME and genomics in ES-SCLC patients.
Journal: Cancer immunology, immunotherapy : CII
Published: July 29, 2024
A novel oral TLR7 agonist orchestrates immune response and synergizes with PD-L1 blockade via type I IFN pathway in lung cancer.
Journal: International immunopharmacology
Published: January 17, 2024
NAT10-mediated upregulation of GAS5 facilitates immune cell infiltration in non-small cell lung cancer via the MYBBP1A-p53/IRF1/type I interferon signaling axis.
Journal: Cell death discovery
Published: September 21, 2023
Clinical characteristics, laboratory abnormalities and CT findings of COVID-19 patients and risk factors of severe disease: a systematic review and meta-analysis.
Journal: Annals of palliative medicine
Published: September 17, 2020
Low-dose carboplatin reprograms tumor immune microenvironment through STING signaling pathway and synergizes with PD-1 inhibitors in lung cancer.
Journal: Cancer letters
Published: June 03, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026